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Abstract
Background: It is often difficult to diagnose inflammatory bowel disease (IBD)-associated neoplasia endoscopically
due to background inflammation. In addition, due to the absence of sensitive tumor biomarkers, countermeasures
against IBD-associated neoplasia are crucial. The purpose of this study is to develop a new diagnostic method
through the application of liquid biopsy.
Methods: Ten patients with IBD-associated cancers and high-grade dysplasia (HGD) with preserved tumor tissue
and blood were included. Tumor and non-tumor tissues were analyzed for 48 cancer-related genes using next-
generation sequencing. Simultaneously, circulating tumor DNA (ctDNA) was analyzed for mutations in the target
genes using digital PCR.
Results: Out of 10 patients, seven had IBD-related cancer and three had IBD-related HGD. Two patients had
carcinoma in situ; moreover, three had stageII and two had stage III. To avoid false positives, the mutation rate
cutoff was set at 5% based on the control results; seven of 10 (70%) tumor tissue samples were mutation-positive.
Mutation frequencies for each gene were as follows: TP53 (20.9%; R136H), TP53 (25.0%; C110W), TP53 (8.5%; H140Q),
TP53 (31.1%; R150W), TP53 (12.8%; R141H), KRAS (40.0%; G12V), and PIK3CA (34.1%; R 88Q). The same mutations
were detected in the blood of these seven patients. However, no mutations were detected in the blood of the
remaining three patients with no tumor tissue mutations. The concordance rate between tumor tissue DNA and
blood ctDNA was 100%.
Conclusion: Blood liquid biopsy has the potential to be a new method for non-invasive diagnosis of IBD-associated
neoplasia.
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Background
It is widely accepted that cancers occur in patients suf-
fering from IBD and these cancers are distinguished
from sporadic colorectal cancers as IBD-associated can-
cers. Eaden et al. [1] reported the incidence rates of
IBD-associated cancers as 2.1%/10 years, 8.5%/20 years,
and 17.8%/30 years, while Rutter et al. [2] reported the
incidence rates as 2.5%/20 years, 7.6%/30 years, and
10.8%/40 years. Although there is a slight variation in
the rates of IBD-associated cancers from several reports
[3], it is still a challenge to prevent IBD-associated can-
cers in patients suffering from IBD.
The functionality of colonoscopy as a surveillance
method for the detection of IBD-associated cancers has
been studied. Although its contribution to colorectal
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cancer detection has long been known, a systemic review
revealed that colonoscopy for IBD diagnosis not only
improves the detection rate of colorectal cancer but also
its effectiveness in colorectal cancer-associated deaths
[4]. However, endoscopic diagnosis of cancer in IBD is
often difficult due to background inflammation, and
countermeasures are imperative.
Randomized biopsy has been used as a surveillance
method for IBD-associated cancers mainly in Europe
and the United States, but the usefulness of targeted bi-
opsy has also been reported with the development of
endoscopic instruments [5]. In addition, the application
of indigo staining and NBI (narrow band imaging) has
been demonstrated in various studies and the surveil-
lance methods have been reviewed [6, 7]. However, none
of these methods provides a breakthrough for the exist-
ing methods and clinicians are still in search for the
other alternatives and improvisations.
On the other hand, new findings about the genes in-
volved in IBD-associated cancers have been reported in
the last few years. Compared to the mutations involved
in sporadic colorectal cancer, the involvement of APC
mutations is lower and new findings such as the involve-
ment of TP53, KRAS, SMAD4, and IDH1 have been re-
vealed [8–12].
Liquid biopsy has been attracting attention as a non-
invasive method for cancer treatment [13]. Traditionally,
a direct biopsy of the tumor is considered to be the only
way to diagnose cancer, but this new method of liquid
biopsy is drawing attention because it can obtain tumor
information from blood, which is comparable to that of
the conventional methods [14]. Endoscopic diagnosis of
cancer in IBD is often difficult due to the background
inflammation and the lack of sensitive tumor bio-
markers. The application of liquid biopsy appears to be
the best for the detection of IBD-associated cancers.
The purpose of the current study was to examine and
detect the presence of mutated genes in blood via circu-
lating tumor DNA (ctDNA) of IBD-associated tumors
and to examine the functionality of liquid biopsy by
comparing tumor tissue DNA with ctDNA.
Methods
Patients and genes
Ten patients with IBD-associated cancers and high-
grade dysplasia, treated at the Okayama University Hos-
pital from 2004 to 2015, with preserved tumor tissue
and blood were included in this study. Tumor tissues
were analyzed using next-generation sequencers, while
blood was simultaneously analyzed for mutations using
digital PCR. We selected 48 cancer-related genes based
on previously published information of whole genome
analysis [10, 11]. These genes included the following:
ABL1, AKT1, ALK, AR, ATM, BRAF, CDKN2A, CSF1R,
CTNNB1, EGFR, ERBB2, ERBB4, FANCA, FANCC,
FANCF, FANCG, FGFR1, FGFR2, FGFR3, FLT3, HRAS,
IDH1, IDH2, JAK2, JAK3, KIT, KRAS, MAP 2 K1,
MAP 2 K2, MAP 2 K4, MET, NOTCH1, NPM1, NRAS,
PDGFRA, PIK3CA, PIK3R1, PTEN, RET, RUNX1,
SMAD4, SMO, SRC, STK11, TP53, VHL, WT1, and
hTERT. All patients provided written informed consent
prior to enrolment. This study was approved by the eth-
ics committee of Okayama University Hospital (1602–
047/1506–070) and conducted in accordance with the
Declaration of Helsinki.
Also, not only non-cancerous tissue samples paired to
cancerous tissue samples but also ten patients with IBD
(5 Crohn and 5 UC) without a tumor have been ob-
served as control in this study.
Extraction of DNA
Formalin fixed paraffin embedded (FFPE) samples were
obtained by surgical resection. Histological examinations
confirmed that these samples contained a minimum of
30% tumor cells. We extracted DNA from 5-μm thick
sections from FFPE samples using a QIAamp DNA FFPE
Tissue Kit (Qiagen, Valencia, CA, USA), according to
the manufacturer’s instructions.
All blood samples were collected prior to initial treat-
ment. DNA was extracted from each source according
to the manufacturer’s instructions. Plasma samples were
separated by centrifugation (3000 rpm, 10 min, 4 °C)
within 3 h of blood collection. The samples were then
stored at − 30 °C for subsequent DNA extraction. Cell
free DNA (cfDNA) was extracted from 1mL of plasma
using the QIAamp Circulating Nucleic Acid Kit (Qiagen,
Hilden, Germany). All DNAs were eluted in a final vol-
ume of 50 μL and stored at − 30 °C. DNAs extracted
from plasma were quantified using a Qubit fluorometer
(Thermo Fisher Scientific, Waltham, MA, USA).
Next-generation sequencing (NGS)
We performed NGS (Miseq, illumina, Hayward, CA,
USA) and deep targeted sequencing for 48 cancer-related
genes in the target custom enrichment panel (Integrated
DNA Technologies, Inc., Coralville, Iowa, USA). In the
present study, geneious prime (Biomatters, Ltd., New
Zealand) was used as the bioinformatics tools for the ana-
lyses. We set the cut-off value at 1% frequency. In addition
to these cut-off values, we set the coverage over 1000. We
excluded the genes for which mutations were detected in
non-cancerous tissue samples in further analysis.
Droplet digital PCR
The presence of mutations was detected via droplet
digital PCR (QX200 system; Bio-Rad Laboratories,
Hercules, CA, USA) using each probe that was designed
from the results of NGS. The probes used are as follows:
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TP53 R136H, KIT N818H, BRAF I452S, ERBB2 V812I,
ATM L3017R, STK11 L195M, PIK3CA R88Q, STK11
R333C, ERBB2 V812L, TP53 C110W, SMAD4 E330D,
AR Y225S, MAP 2 K4 R134Q, PDGFRA F837V, PDGF
RA I843S, KRAS G12V, KIT W553C, KIT Y819S, TP53
R150W, ATM L2890I, RUNX1 P403L, TP53 H140Q,
MAP 2 K4 S184L, MAP 2 K4 V321M, TP53 R141H,
RUNX1 N233T, IDH2 R172G, PDGRFA R558H, AR
C612S, and FGFR3 K537E. DNA eluent (5 μL) from
plasma was mixed with Droplet PCR Supermix (10 μL;
Bio-Rad Laboratories, Hercules, CA, USA), primer/probe
mixture (2 μL), and sterile DNase- and RNase-free water
(5 μL). The mixture (22 μL) was added to droplet gener-
ation oil (70 μL; Bio-Rad Laboratories, Hercules, CA,
USA) to produce a droplet. The emulsion was subjected
to PCR in a thermal cycler and the conditions were as
follows: an initial temperature of 95 °C for 10 min, 40 cy-
cles at 94 °C for 30 s, and 55 °C for 1 min. A final step
was performed at 98 °C for 10 min for enzyme deactiva-
tion and the reaction mixtures were analyzed using a
droplet reader (Bio-Rad Laboratories, Hercules, CA,
USA). For quantification, fluorescence signal readout
was obtained using QuantaSoft software (Bio-Rad La-
boratories, Hercules, CA, USA). In this study, we set the
minimum number of events used to call positivity at one
droplet, and the threshold of fluorescence intensity at
1200 using a positive control and a negative control,
which were artificial gene synthesis products. All experi-
ments were conducted in duplicates to diminish the ef-
fect of a false negative result, although its probability
was low in these materials. A result was considered posi-
tive even if it occurred once.
Results
Patient characteristics
There were eight cases of ulcerative colitis and two cases
of Crohn’s disease. The median age of the patients was
49 years, comprising of four males and six females. Out
of the 10 patients, seven had IBD-associated cancer and
three had high-grade dysplasia. Two patients had carcin-
oma in situ; moreover, three had stageII and two had
stageIII (Table 1).
The patient background for each of the cases is as fol-
lows: cases 1 and 2 have Crohn’s disease; cases 3 to 10
have ulcerative colitis; cases 1 to 5 have advanced can-
cer; cases 6 to 10 have carcinoma in situ and/or HGD.
Tumor DNA mutation analysis was performed on these
cases using next-generation sequencers (Table 1).
The NGS analysis
The NGS analysis of tumor tissue DNA showed the fol-
lowing results: in case 1, TP53 was 20.9%; in case 2,
PIC3CA was 34.1%; in case 3, TP53 was 25.7%; in case
4, KRAS was 40%; in case 5, TP53 was 31.1%; in case 6,
TP53 was 8.5%; in case 7, TP53 was 12.8%; in case 8,
IDH2 was 1.1%; in case 9, AR was 1.5%; and in case 10,
FGFR3 was 1.0% in frequency (Table 2).
The NGS of control showed that there were no genes
more than 3% in frequency (Supplemental 1).
The digital PCR analysis
The following are the results of digital PCR analysis of
blood ctDNA: detection of TP53 in case 1, PIC3CA in
case 2, TP53 in case 3, KRAS in case 4, TP53 in case 5,
TP53 in case 6, and TP53 in case 7. However, we were
Table 1 Patient characteristics

















1 CD 42 M ileocolonic 15 Rectum 5 Muc 3 Surgery 3.7 10.5 7.3
2 CD 70 M Ileal 20 Ileum 5 Por 2 Surgery 1.9 27.4 0
3 UC 35 M Pancolitis 26 Ascending 2 Por 2 Surgery 2.7 10.8 0.05
4 UC 62 F Pancolitis 36 Sigmoid 5 Muc 3 Surgery 3.0 18.2 0.2
5 UC 48 F Pancolitis 25 Rectum 5 Muc 2 Surgery 1.2 8.8 3.7
6 UC 40 F Pancolitis 14 Rectum 0-IIb HGD – Surgery 1.7 30.9 0.02
7 UC 49 F Left-sided 7 Sigmoid 0-
IIa +
IIb
HGD – ESD 1.3 9.4 0.04
8 UC 83 F Pancolitis 17 Rectum 0-IIa HGD – Surgery 1.5 7.6 0.4
9 UC 53 M Pancolitis 30 Rectum 0-IIc Tub1 Tis Surgery 2.7 8.1 0.05
10 UC 34 F Left-sided 14 Rectum 0-Ia Pap Tis Surgery 0.2 10.5 0.06
Abbreviation: IBD inflammatory bowel disease, UC Ulcerative colitis, CD Crohn disease, M Male, F Female, I Ileum, A ascending colon, S sigmoid colon, R Rectum,
ESD Endoscopic submucosal dissection, tub1 well differentiated tubular adenocarcinoma, tub2 moderately differentiated tubular adenocarcinoma, pap papillary
adenocarcinoma, muc mucinous adenocarcinoma, por poorly differentiated adenocarcinoma, HGD high grade dysplasia, Tis carcinoma in situ
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unable to detect cases 8, 9, and 10, which had low muta-
tion frequencies in tumor tissue DNA. Interestingly, the
high frequency of the tumor tissue DNA mutation,
especially those with a frequency of 5% or higher, could
be detected by blood ctDNA. Amino acid substitutions
due to mutations in tissue DNA and blood ctDNA also
Table 2 The next-generation sequencing and the digital PCR analysis in case 1 to 10
Case no. Tumor tissue DNA Blood ctDNA
1
Gene TP53 KIT BRAF ERBB2 ATM STK11 TP53 KIT BRAF ERBB2 ATM STK11
AA R136H N818H I452S V812I L3017R L195M R136H – – – – –
Freq(%) 20.9 1.7 1 1.2 1.2 1.2 3.1 – – – – –
2
Gene PIK3CA STK11 ERBB2 PIK3CA STK11 ERBB2
AA R88Q R333C V812L R88Q – –
Freq(%) 34.1 2.6 2.4 5.3 – –
3
Gene TP53 SMAD4 AR MAP 2 K4 PDGFRA PDGFRA TP53 SMAD4 AR MAP 2 K4 PDGFRA PDGFRA
AA C110W E330D Y225S R134Q F837V I843S C110W – – – – –
Freq(%) 25.7 2.2 1.8 1.4 1 1 7.8 – – – – –
4
Gene KRAS KIT KIT KRAS KIT KIT
AA G12V W553C Y819S G12V – –
Freq(%) 40 1.2 1.1 7.7 – –
5
Gene TP53 ATM RUNX1 TP53 ATM RUNX1
AA R150W L2890I P403L R150W – –
Freq(%) 31.1 3.3 1.1 50.7 – –
6
Gene TP53 MAP 2 K4 MAP 2 K4 TP53 MAP 2 K4 MAP 2 K4
AA H140Q S184L V321M H140Q – –
Freq(%) 8.5 2.1 1.1 3.9 – –
7
Gene TP53 RUNX1 TP53 RUNX1
AA R141H N233T R141H –
Freq(%) 12.8 9.1 6.3 –
8
Gene IDH2 PDGFRA IDH2 PDGFRA
AA R172G R558H – –









Abbreviation: AA amino acid, Freq frequency, ctDNA circulating tumor DNA
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correlated with each other, thus suggesting that the
ctDNA in these cases originated in tumor tissue DNA
(Table 2).
If we consider more than 5% of the tumor tissue DNA
mutations to be positive, it would result in three wild
type and seven mutation cases. For these cases, the re-
sults of blood ctDNA detection via liquid biopsy also
confirmed three wild type and seven mutation cases.
Therefore, the concordance rate was 100% (Table 3).
Liquid biopsy in ten patients with ulcerative colitis
without a tumor showed there was no detected genes
(Supplemental 1).
Discussion
In this study, the detection of blood ctDNA in IBD-
associated tumors was performed. The concordance rate
between tumor tissue DNA and blood ctDNA was 100%,
thereby suggesting the possibility of a non-invasive
method. Interestingly, liquid biopsy was also useful for
high-grade dysplasia cases, but a certain frequency of
tumor tissue DNA mutations was required for the detec-
tion of blood ctDNA mutations.
Our previous studies revealed that ctDNA mutations
require more than 10% frequency rate of target tumor
tissue DNA mutations [15–17]. The current results,
therefore, corroborated the previous studies. Although
cancerous lesions and non-cancerous lesions in patients
with IBD had a few types of mutations due to carcino-
genesis and inflammation, the key driver mutations had
much higher frequency. For this reason, liquid biopsy
might be an ideal method because only high frequency
mutations could be detected by blood ctDNA.
Although the utility of liquid biopsy has recently been
demonstrated in various fields, there have been no re-
ports on detection of IBD-associated neoplasia using this
technique. This may be due to the lack of centers that
handle large numbers of cases and the need to target a
large number of genes. However, this is the first study to
report the use of this technique for the detection of
IBD-associated neoplasia.
There are few limitations in this study. First, this is a
single-center, small-scale, retrospective, observational
study, so that a multicenter, large-scale, prospective
study will be required. Based on these results, a pro-
spective validation study is underway. Second, the study
evaluates only 48 genes and higher detection rate can be
achieved by combining other genetic mutations in future
studies. Third, the origin of gene mutation in blood is
unknown. This hinders the clinical application of liquid
biopsy; however, in this study, we compared tumor tis-
sue DNA and blood ctDNA mutations and even con-
firmed a match between the mutation locations, and
therefore, conclude that the ctDNA was derived from
cancer tissues. Forth, although DNA is usually stable for
long time, we have not examined the effect of the stor-
age time on this analysis. The storage period might be
one of the limitations in future studies. Fifth, cfDNA
quantity in blood might limit the detection in early stage
disease. Sixth, although biopsy samples were not used in
this study, laser microdissection might help to capture
the dysplastic areas in that case.
Conclusion
Blood liquid biopsy has the potential to be a new
method for non-invasive diagnosis of IBD-associated tu-
mors and may develop as one of the next-generation de-
tection techniques in future. Although further molecular
biological analysis will be required to narrow down the
candidate genes for future use in screening, it could be a
very useful method for monitoring.
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